Lack of activity of 5-fluorouracil plus mitomycin-C as salvage therapy in cisplatin-resistant epithelial ovarian cancer: results of a phase II trial.
Twenty-five patients with progressive, cisplatin-resistant epithelial ovarian cancer received 5-Fluorouracil (5-FU) 500 mg/m2 days one through three and Mitomycin-C 10 mg/m2 every 28 days in a phase II trial. Myelotoxicity manifested as thrombocytopenia resulted in dose reduction, delay of therapy, or discontinuation of treatment in 24% of patients. Only two patients (8%) demonstrated a partial response to therapy. Neither response was durable. The majority of patients (76%) demonstrated progression of disease following a single course of therapy. As utilized in this trial, the combination of 5-FU and Mitomycin-C is not an active salvage regimen for patients with cisplatin-resistant, progressive epithelial ovarian cancer.